We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. Qualitest’s headquarters and distribution facilities are located in Huntsville, Alabama and a workforce of more than 1,100 employees in Huntsville and Charlotte, North Carolina.Įndo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Thirty-two of Qualitest’s products are listed among the top 250 generics by total prescription (TRx) volume. The company’s broad range of generics encompasses 175 product families. generics company as measured by prescriptions filled. General Healthcare Group, the largest private hospital group in the UK Capio, a leading pan-European hospital group Unilabs, a leading European clinical laboratory business and Apollo, India’s largest private hospital group.įounded in 1983, Qualitest is the sixth largest U.S.
#Endo pharmaceuticals huntsville alabama trial#
Significant recent investments by the Apax Partners Healthcare team include: Marken, a global leader in clinical trial logistics TriZetto, a leading healthcare IT company in the U.S. Healthcare is one of the five sectors in which Apax Partners focuses exclusively. Morgan Securities LLC is acting as exclusive financial advisor to Qualitest Pharmaceuticals and Kirkland & Ellis LLP is acting as Qualitest Pharmaceuticals’ legal counsel. The transaction is subject to regulatory review, including clearance by the relevant antitrust authorities, and is expected to close late in the fourth quarter of 2010 or early in the first quarter of 2011. I am convinced that this combination will enable our management team and employees to accelerate the growth of our business and continue the important work we do here at Qualitest.” I am confident Qualitest’s unique capabilities as a leading generics provider ideally complement Endo’s diversified businesses. Today’s announcement brings together two highly successful businesses that I believe are an excellent fit. Marvin Samson, Chairman and Chief Executive Officer of Qualitest Pharmaceuticals, commented, “Apax has been an exceptional partner for the Qualitest team since 2007, and we thank them for their contributions as we grew the company while maintaining our unwavering dedication to compliance. Qualitest, and now Endo, represents an important part of the solution to the challenges faced by the U.S. by supplying high-quality, cost-effective pharmaceuticals. Qualitest, a portfolio company of Apax Partners since 2007, is the sixth largest generic pharmaceutical company in the U.S.īuddy Gumina, Partner and Co-Head of Global Healthcare at Apax, said, "We have been proud to work with the management team at Qualitest Pharmaceuticals over the past three years as they have built one of the leading generics businesses in the U.S. New York, Septem– Apax Partners today announced that Endo Pharmaceuticals (Nasdaq: ENDP) has entered into a definitive agreement to acquire Qualitest Pharmaceuticals for approximately $1.2 billion in cash. Apax Partners to Sell Qualitest Pharmaceuticals to Endo Pharmaceuticals for $1.2 Billion 29th September 2010 Apax New York, Septem– Apax Partners today announced that Endo Pharmaceuticals (Nasdaq: ENDP) has entered into a definitive agreement to acquire Qualite Home > News & Views > Apax Partners to Sell Qualitest Pharmace.
0 kommentar(er)
